-
Signature
-
/s/ Vijay Iyer, Attorney-in-Fact
-
Stock symbol
-
BKNG
-
Transactions as of
-
Nov 17, 2025
-
Transactions value $
-
-$2,135,414
-
Form type
-
4
-
Date filed
-
11/19/2025, 07:30 AM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Fogel Glenn D |
CEO AND PRESIDENT, Director |
BOOKING HOLDINGS INC., 800 CONNECTICUT AVENUE, NORWALK |
/s/ Vijay Iyer, Attorney-in-Fact |
2025-11-19 |
0001516908 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BKNG |
Common Stock |
Sale |
-$47.8K |
-10 |
-0.04% |
$4,775.17 |
22.6K |
Nov 17, 2025 |
Direct |
F1, F2 |
| transaction |
BKNG |
Common Stock |
Sale |
-$95.5K |
-20 |
-0.09% |
$4,777.43 |
22.6K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$95.9K |
-20 |
-0.09% |
$4,796.35 |
22.5K |
Nov 17, 2025 |
Direct |
F1, F3 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48K |
-10 |
-0.04% |
$4,798.75 |
22.5K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$130K |
-27 |
-0.12% |
$4,800.52 |
22.5K |
Nov 17, 2025 |
Direct |
F1, F4 |
| transaction |
BKNG |
Common Stock |
Sale |
-$312K |
-65 |
-0.29% |
$4,801.97 |
22.4K |
Nov 17, 2025 |
Direct |
F1, F5 |
| transaction |
BKNG |
Common Stock |
Sale |
-$144K |
-30 |
-0.13% |
$4,804.12 |
22.4K |
Nov 17, 2025 |
Direct |
F1, F6 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.1K |
-10 |
-0.04% |
$4,806.22 |
22.4K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.1K |
-10 |
-0.04% |
$4,808.58 |
22.4K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$96.3K |
-20 |
-0.09% |
$4,812.71 |
22.4K |
Nov 17, 2025 |
Direct |
F1, F7 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.1K |
-10 |
-0.04% |
$4,813.74 |
22.4K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.2K |
-10 |
-0.04% |
$4,822.16 |
22.4K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$145K |
-30 |
-0.13% |
$4,824.10 |
22.3K |
Nov 17, 2025 |
Direct |
F1, F8 |
| transaction |
BKNG |
Common Stock |
Sale |
-$145K |
-30 |
-0.13% |
$4,826.95 |
22.3K |
Nov 17, 2025 |
Direct |
F1, F9 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.3K |
-10 |
-0.04% |
$4,830.21 |
22.3K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.3K |
-10 |
-0.04% |
$4,831.94 |
22.3K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.4K |
-10 |
-0.04% |
$4,835.72 |
22.3K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$53.2K |
-11 |
-0.05% |
$4,838.78 |
22.3K |
Nov 17, 2025 |
Direct |
F1, F10 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.4K |
-10 |
-0.04% |
$4,840.94 |
22.2K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.5K |
-10 |
-0.04% |
$4,847.98 |
22.2K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$97K |
-20 |
-0.09% |
$4,849.14 |
22.2K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.6K |
-10 |
-0.05% |
$4,856.95 |
22.2K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$97.3K |
-20 |
-0.09% |
$4,865.07 |
22.2K |
Nov 17, 2025 |
Direct |
F1, F11 |
| transaction |
BKNG |
Common Stock |
Sale |
-$48.7K |
-10 |
-0.05% |
$4,867.82 |
22.2K |
Nov 17, 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
-$97.4K |
-20 |
-0.09% |
$4,870.76 |
22.2K |
Nov 17, 2025 |
Direct |
F1, F12 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: